

**Ran Reshef, MD**

**Professor of Medicine at CUIMC**

Director, Cellular Immunotherapy

Deputy Director, Blood and Marrow Transplantation and Cell Therapy Program

New-York Presbyterian Hospital/Columbia University Irving Medical Center

New York, NY

Ran Reshef, MD is the Director of the Cellular Immunotherapy Program at Columbia University Irving Medical Center in New York. He oversees the management of patients receiving commercially available CAR-T and experimental cell therapies in clinical trials. He directs a research lab in the Columbia Center for Translational Immunology, and he is a member of the NCI-designated Herbert Irving Comprehensive Cancer Center.

Dr. Reshef's research revolves around development of immunotherapy approaches for the treatment of cancer and his lab studies novel ways to improve the efficacy and the safety of immunotherapies including bone marrow transplants, checkpoint inhibitors and cell therapies. Specific areas of interest include lymphocyte trafficking mechanisms, the enteroendocrine system in controlling immunotherapy complications in the GI tract, and development of single cell technologies for evaluation of human biospecimens related to cancer immunotherapy. The lab's ultimate goal is to improve cell therapy and transplant outcomes using evidence in both mice and humans and to test novel targets and biomarkers clinically.

Dr. Reshef has authored or co-authored more than 100 original research publications related to translational immunology and is an R01-funded investigator and active or past recipient of awards from ASH, NCI, NHLBI, Conquer Cancer Foundation, Department of Defense, National Marrow Donor Program, and the Leukemia and Lymphoma Society.